Maxcyte (DI) (MXCT)

 122.00p
   
  • Change Today:
      0.000p
  • 52 Week High: 239.00
  • 52 Week Low: 115.00
  • Currency: UK Pounds
  • Shares Issued: 51.36m
  • Volume: 505
  • Market Cap: £62.66m
  • Beta: 0.02

MaxCyte buddies-up with Gilead subsidiary

By Duncan Ferris

Date: Monday 12 Nov 2018

LONDON (ShareCast) - (Sharecast News) - Cell-based medicines and life sciences company MaxCyte confirmed on Monday that it has entered into a research agreement with Kite, a subsidiary of American biotechnology giant Gilead.
The agreement between the two parties will see Kite gain access to MaxCyte's flow electroporation technology platform, which can transfect any cell type using a single, chemically-defined electroporation buffer, to enable non-viral cell engineering.

The London-listed company's strategy is to provide the technology to partners in order to advance the development of cutting-edge medicines, particularly in cell therapy, including the use of gene editing tools in the treatment of inherited genetic diseases and immuno-oncology approaches to treating cancer.

Kite, meanwhile, is a biopharmaceutical company engaged in the development of cancer immunotherapies with a goal of providing rapid, long-term, durable response and eliminating the burden of chronic care.

Doug Doerfler, president and chief executive of MaxCyte, said: "We're excited to provide Kite the ability to leverage our versatile cell engineering platform to enable gene-editing technologies for research and development of important new therapeutics. This agreement further underlines MaxCyte's position as a leader in non-viral cell engineering for cell therapies."

MaxCyte's shares were up 0.51% at 199.00p at 1255 GMT.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

Maxcyte (DI) Market Data

Currency UK Pounds
Share Price 122.00p
Change Today 0.000p
% Change 0.00 %
52 Week High 239.00
52 Week Low 115.00
Volume 505
Shares Issued 51.36m
Market Cap £62.66m
Beta 0.02

Maxcyte (DI) Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value Not Available
Price Trend Not Available
Income Not Available
Growth Not Available

What The Brokers Say

Strong Buy 2
Buy 0
Neutral 0
Sell 0
Strong Sell 0
Total 2
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Maxcyte (DI) Dividends

No dividends found

Trades for 23-Sep-2019

Time Volume / Share Price
10:15 505 @ 120.00p

Maxcyte (DI) Key Personnel

CEO Doug Doerfler
CFO Ron Holtz

Top of Page